Broderick Brian C Raises Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Broderick Brian C increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 22.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,560 shares of the medical instruments supplier’s stock after buying an additional 1,005 shares during the period. Broderick Brian C’s holdings in Becton, Dickinson and Company were worth $1,376,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Livelsberger Financial Advisory purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $27,000. OLD Point Trust & Financial Services N A acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. DiNuzzo Private Wealth Inc. acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $30,000. Scarborough Advisors LLC acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $32,000. Finally, Accordant Advisory Group Inc acquired a new position in Becton, Dickinson and Company in the first quarter valued at approximately $35,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BDX. Citigroup lowered their price target on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a report on Wednesday. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 27th. Evercore ISI decreased their price objective on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They set a “buy” rating and a $274.00 price target for the company. Finally, Barclays upped their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $280.14.

Becton, Dickinson and Company Price Performance

Shares of BDX traded up $1.13 during trading hours on Thursday, reaching $225.00. 1,849,424 shares of the company traded hands, compared to its average volume of 1,433,974. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $65.03 billion, a PE ratio of 49.56, a price-to-earnings-growth ratio of 1.97 and a beta of 0.42. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $287.32. The stock has a fifty day simple moving average of $233.03 and a 200 day simple moving average of $237.02.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating the consensus estimate of $2.97 by $0.20. The company had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.86 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 28th. Shareholders of record on Monday, June 10th were issued a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 1.69%. The ex-dividend date of this dividend was Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now directly owns 1,976 shares in the company, valued at $472,876.56. The disclosure for this sale can be found here. Insiders sold 8,615 shares of company stock worth $2,033,381 in the last 90 days. 0.31% of the stock is owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.